Modality
mAb
MOA
WRNi
Target
TIM-3
Pathway
Hedgehog
Hemophilia AWilms
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Oct 2030
Phase 1Current
NCT07994556
13 pts·Wilms
2020-10→2030-10·Not yet recruiting
13 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-094.5y awayPh2 Data· Wilms
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2030-10-09 · 4.5y away
Wilms
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07994556 | Phase 1/2 | Wilms | Not yet recr... | 13 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα |